Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Dow
McKinsey
Moodys
Merck

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Litigation Details for VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. MYLAN PHARAMACEUTICALS, INC. (D.N.J. 2017)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. MYLAN PHARAMACEUTICALS, INC. (D.N.J. 2017)

Docket   Start Trial Date Filed 2017-09-01
Court District Court, D. New Jersey Date Terminated 2018-06-04
Cause 35:271 Patent Infringement Assigned To Stanley R. Chesler
Jury Demand None Referred To Cathy L. Waldor
Parties ACTAVIS LLC; MYLAN INC.; MYLAN LABORATORIES LTD.; MYLAN PHARAMACEUTICALS, INC.; PROGENICS PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, INC.; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; WYETH LLC
Patents 8,247,425; 8,420,663; 8,552,025; 8,822,490; 9,180,125; 9,492,445; 9,669,096
Attorneys AMY DANIELLE LURIA; J. BRUGH LOWER; JASON B. LATTIMORE; WILLIAM P. DENI , JR.
Firms Critchley Kinum & Denoia LLC; Law Office of Jason B. Lattimore, Esq.
Link to Docket External link to docket
Small Molecule Drugs cited in VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. MYLAN PHARAMACEUTICALS, INC.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for VALEANT PHARMACEUTICALS INTERNATIONAL, INC. v. MYLAN PHARAMACEUTICALS, INC. (D.N.J. 2017)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 11 inter alia, the ’096 patent, the ’445 patent, and U.S. Patent Nos. 8,247,425, 8,420,663, 8,552,025, …“the Orange Book”), together with U.S. Patent Nos. 8,247,425, 8,420,663, 8,552,025, 8,822,490, and 9,…against Defendants with respect to U.S. Patent Nos. 8,247,425, 8,420,663, 8,552,025, 8,822,490, and …United States Patent Nos. 9,669,096 (“the ’096 patent”) and 9,492,445 (“the ’445 patent”) arising under…United States Patent Nos. 9,669,096 (“the ’096 patent”) and 9,492,445 (“the ’445 patent”) arising under External link to document
0000-00-00 32 Stipulation and Order #39; U.S. Patent No. 9,669,096 (“'096 Patent”) and U.S. Patent No. 9,492,445 (“’445 Patent”) asserted…’096 Patent and ’445 Patent in any future litigation over the ’096 Patent and/or the ’445 Patent pertaining…l£ag%ez2 op4lba §?:§\B|DZBZSS the ’096 Patent and ’445 Patent would be infringed by any unlicensed manufacturel…be enjoined until expiration of the ’096 Patent and ’445 Patent from (i) making, using, offering to sell… importing until expiration of the ’096 Patent and ’445 Patent the Actavis Products in the United States External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
McKesson
Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.